Want to see JP:4588 full AI Analyst Report?
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥668.00 - ¥7,960.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.37M
Market Cap
¥218.59B
Enterprise Value¥84.23B
Total Cash (Recent Filing)¥3.72B
Total Debt (Recent Filing)¥320.02M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-81.78
Shares Outstanding29,575,700
10 Day Avg. Volume1,101,960
30 Day Avg. Volume1,367,600
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageImproving debt-to-equity and a larger equity base provide greater financial capacity than a highly leveraged structure would. This can support continued research investment and give the company more flexibility to pursue development and commercialization activities over the next several quarters.
Biotech Pipeline ModelA model centered on novel therapeutics and partnership-led commercialization can create multiple opportunities to advance assets without relying solely on internal commercial infrastructure. If candidates progress, this structure may expand future revenue channels and strategic optionality.
Positive Gross ProfitPositive gross profit indicates that the company has generated economic value above reported revenue costs in recent periods, despite its broader losses. This provides a foundation for improved operating leverage if development progress or commercialization produces a substantial and sustained revenue inflection.
Bears Say
Revenue CollapseThe steep multi-year revenue decline shows that the current business has not maintained its earlier revenue scale. Persistently low revenue reduces internal funding capacity, increases dependence on future product or partnership milestones, and makes recovery dependent on a major commercial inflection.
Persistent Operating LossesLarge recurring operating and net losses indicate that current revenue does not cover the company’s cost base. Unless revenue grows materially or expenses are reset, continued losses can erode equity, constrain investment choices, and increase the need for external funding over the medium term.
Heavy Cash BurnConsistently negative operating and free cash flow shows that the business is not self-funding its research and development activities. Continued heavy burn can require recurring financing, limit strategic flexibility, and expose shareholders to dilution or other funding pressure if losses persist.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥668.00 and its highest was ¥7960.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥218.59B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 7 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on Aug 07, 2026. The company reported -¥11.87 earnings per share for the quarter.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,575,700 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥11.87 in its last earnings report. Following the earnings report the stock price went up 1.751%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.